Hansa Biopharma AB (publ) (STO:HNSA)

Sweden · Delayed Price · Currency is SEK

34.36

+1.46 (4.44%)

At close: Dec 30, 2025

Revenue by Product

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2006 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2006 - 2019
Antibody-cleaving Enzyme Technology Platform	171.32M	Log In	Log In	Log In	Log In	Upgrade
Antibody-cleaving Enzyme Technology Platform Growth	27.76%	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2006 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2006 - 2019
Europe	140.24M	Log In	Log In	Log In	Log In	Upgrade
Europe Growth	31.46%	Log In	Log In	Log In	Log In	Upgrade
North America	27.96M	Log In	Log In	Log In	Log In	Upgrade
North America Growth	1.97%	Log In	Log In	Log In	Log In	Upgrade
Sweden	3.12M	Log In	Log In	Log In	Log In	Upgrade
Sweden Growth	-	Log In	Log In	Log In	Log In	Upgrade